Shilpi Medicare announced yesterday after market hours that two of its API sites in Karnataka have received GMP compliance certificate from Japan’s health regulator, PMDA.

Good manufacturing practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.

In India GMP inspections are carried out by state Food and Drugs Administrations (FDA) and these FDA report to the Central Drugs Standard Control Organization.

The stock price of Shilpi Medicare is up in the green, over 11% up at Rs.486 and this is after hitting an intra day high at Rs.503.65.